Pricing Log in Create free account
Friday 6 November 2026 Export BIIB’s income statement to Excel — free account

Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue
+10.6%
EPS
−104.4%
Free cash flow
−69.3%
Total debt
+16.0%

Quarter to September 2026, against a year earlier

248.43 4.50 +1.84%
Market cap
$36.1B
P/E
104×
Fwd P/E
47.4×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Biogen Inc. 8-K/A filed Jun 10, 2026

Period ended May 14, 2026 · Filed · accepted 4:49 PM ET · Document on sec.gov · Filing index

9.01 Financial statements and exhibits

Nothing in this filing raised a red flag. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov